Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms

Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease prevention. The deals mark a strategic push for Lilly into vaccine development, an area the company said aligns with its broader goal of addressing major global health challenges beyond its core diabetes and obesity portfolio, which has been a key driver of recent cash flow.